IngentaConnect Role of radiation therapy in the treatment of stage I/II mucosa-a...

Authors: Tsai, HK; Li, S; Ng, AK; Silver, B; Stevenson, MA; Mauch, PM

Source: Annals of Oncology, Volume 18, Number 4, 1 April 2007 , pp. 672-678(7)

Abstract:

Background: Few large studies exist on the outcome of patients treated for stage I/II mucosa-associated lymphoid tissue (MALT) lymphoma.

Patients and methods: We retrospectively reviewed the records of 77 patients consecutively treated for stage I (n = 66) or II (n = 11) MALT lymphoma at our institution. Progression-free survival (PFS), freedom from treatment failure (FFTF), and overall survival (OS) were calculated using the Kaplan-Meier method.

Results: The median follow-up time was 61 months (range 2-177 months). Fifty-two patients (68%) received local radiation therapy (RT) alone, 17 (22%) had surgery followed by adjuvant RT, five (6%) had surgery alone, two (3%) had surgery and chemotherapy, and one patient had chemotherapy alone. The median RT dose was 30 Gy (range 18-40 Gy). The 5-year PFS, FFTF, and OS rates were 76%, 78%, and 91%, respectively. The 5-year PFS (79% versus 50%; P = 0.002) and FFTF (81% versus 50%; P = 0.0004) rates were higher for patients who received RT as compared with patients who did not.

Conclusions: The prognosis following treatment of stage I/II MALT lymphoma is excellent. RT improves PFS and FFTF and has an important role in the curative treatment of patients with localized disease.

Keywords: chemotherapy; MALT lymphoma; outcome; radiotherapy; surgery

Document Type: Research article

DOI: 10.1093/annonc/mdl468

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$40.03 plus tax Refund Policy

Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma